Moderna’s Q3 2026 results delivered a significant turnaround. Revenue reached $1.3B, up 29% year over year, while the company returned to profitability with $162M in net income, compared with a $200M loss in Q3 2025. Diluted EPS also improved from -$0.51 to $0.38. Moderna raised its 2026 revenue growth outlook to 15%–25%. Meanwhile, the MRNA/USD market snapshot on @DecibelTrade shows an Oracle price of $257.49, up 6.29% over 24 hours. The earnings show the business turnaround. The market chart gives another perspective on how traders are responding.
AlwaysfaaShare
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.